Plasma-derived Exosomal miR-25-3p and miR-23b-3p as Predictors of Response to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

  • 0Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic of China.

|

|

Summary

This summary is machine-generated.

Exosomal miR-25-3p and miR-23b-3p show promise in predicting chemoradiotherapy response in esophageal cancer. MiR-25-3p also serves as a prognostic marker for progression-free survival in these patients.

Area Of Science

  • Oncology
  • Biomarker Discovery
  • Molecular Diagnostics

Background

  • Exosomal microRNAs (miRNAs) are emerging as crucial biomarkers in oncology.
  • The predictive role of exosomal miRNAs in esophageal squamous cell carcinoma (ESCC) response to chemoradiotherapy (CRT) remains largely unexplored.

Purpose Of The Study

  • To investigate the potential of exosomal miRNAs as predictive biomarkers for CRT response in ESCC patients.
  • To identify specific exosomal miRNAs that can differentiate responders from non-responders to CRT.

Main Methods

  • Prospective enrollment of 40 ESCC patients undergoing CRT.
  • Plasma exosome isolation using the EXODUS platform.
  • Small RNA sequencing for miRNA discovery in responders vs. non-responders, followed by qRT-PCR validation in an extended cohort.

Main Results

  • Five differentially expressed exosomal miRNAs were identified in the discovery phase.
  • Exosomal miR-23b-3p and miR-25-3p demonstrated significant ability to distinguish responders from non-responders (AUCs 0.708 and 0.932, respectively).
  • Low miR-25-3p levels correlated with shorter progression-free survival (PFS), and miR-25-3p was identified as an independent predictive biomarker for PFS.

Conclusions

  • Exosomal miR-25-3p and miR-23b-3p are promising biomarkers for predicting early CRT effectiveness in locally advanced ESCC.
  • Exosomal miR-25-3p represents a novel prognostic marker for ESCC.
  • Larger prospective studies are warranted to confirm their clinical utility for personalized treatment decisions.